glp-1 fda approved Wegovy Pill Wins Approval as First Oral Treatment for Obesity and Weight Loss FDA Approves Wegovy Alternative for

Its one of the GLP-1 meds, one person wrote

During the 24-week observation, liraglutide did not improve LVEF but rather caused more death, ventricular arrhythmia, and atrial fibrillation, compared with the placebo

These abnormalities persist even with a reduced metabolic rate, indicating that vulnerability arises mainly from impaired antioxidant defense rather than increased energy demand (110)

Requirements for other Ozempic-related claims may also change

Article PubMed Google Scholar Download references Related Articles Obesity drugs: huge study identifies new health risks Why do obesity drugs seem to treat so many other ailments

For more information, ask your doctor or pharmacist